Neuronetics, Inc. $STIM Shares Acquired by UBS Group AG

UBS Group AG lifted its holdings in shares of Neuronetics, Inc. (NASDAQ:STIM) by 20.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,607,047 shares of the company’s stock after acquiring an additional 442,216 shares during the quarter. UBS Group AG owned about 3.81% of Neuronetics worth $3,598,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Presidio Capital Management LLC lifted its holdings in shares of Neuronetics by 217.0% during the 4th quarter. Presidio Capital Management LLC now owns 37,436 shares of the company’s stock valued at $52,000 after acquiring an additional 25,625 shares in the last quarter. David J Yvars Group lifted its holdings in shares of Neuronetics by 22.1% during the 4th quarter. David J Yvars Group now owns 31,230 shares of the company’s stock valued at $43,000 after acquiring an additional 5,650 shares in the last quarter. Wexford Capital LP lifted its holdings in shares of Neuronetics by 83.1% during the 3rd quarter. Wexford Capital LP now owns 1,177,225 shares of the company’s stock valued at $3,214,000 after acquiring an additional 534,155 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new position in shares of Neuronetics during the 3rd quarter valued at $33,000. Finally, National Bank of Canada FI lifted its holdings in shares of Neuronetics by 27.5% during the 3rd quarter. National Bank of Canada FI now owns 31,880 shares of the company’s stock valued at $87,000 after acquiring an additional 6,880 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Neuronetics from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Canaccord Genuity Group reduced their target price on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, March 19th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $3.00.

Neuronetics Stock Performance

Shares of STIM stock opened at $1.20 on Friday. Neuronetics, Inc. has a 12 month low of $0.80 and a 12 month high of $4.85. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.67 and a quick ratio of 1.50. The firm has a market capitalization of $83.51 million, a P/E ratio of -2.22 and a beta of 1.13. The company’s fifty day moving average price is $1.48 and its two-hundred day moving average price is $1.58.

Neuronetics (NASDAQ:STIM) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Neuronetics had a negative net margin of 24.48% and a negative return on equity of 139.83%. The firm had revenue of $34.45 million for the quarter, compared to analyst estimates of $34.17 million. On average, research analysts anticipate that Neuronetics, Inc. will post -0.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Jorey Chernett acquired 607,400 shares of the business’s stock in a transaction on Wednesday, March 18th. The shares were purchased at an average price of $1.35 per share, for a total transaction of $819,990.00. Following the acquisition, the insider directly owned 8,123,804 shares of the company’s stock, valued at $10,967,135.40. This represents a 8.08% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Keith J. Sullivan sold 46,289 shares of the business’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $1.34, for a total transaction of $62,027.26. Following the completion of the transaction, the director owned 1,590,924 shares in the company, valued at $2,131,838.16. This represents a 2.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders acquired 2,432,872 shares of company stock worth $3,184,906 and sold 90,604 shares worth $121,528. Insiders own 8.40% of the company’s stock.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.